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Abstract
Inflammatory bowel diseases (IBD) are chronic and relapsing inflammatory
conditions of the gut that include Crohn's disease and ulcerative colitis. The
pathogenesis of IBD is not completely unraveled, IBD are multi-factorial diseases
with reported alterations in the gut microbiota, activation of different immune
cell types, changes in the vascular endothelium, and alterations in the tight
junctions’ structure of the colonic epithelial cells. Proteomics represents a useful
tool to enhance our biological understanding and to discover biomarkers in blood
and intestinal specimens. It is expected to provide reproducible and quantitative
data that can support clinical assessments and help clinicians in the diagnosis and
treatment of IBD. Sometimes a differential diagnosis of Crohn's disease and
ulcerative colitis and the prediction of treatment response can be deducted by
finding meaningful biomarkers. Although some non-invasive biomarkers have
been described, none can be considered as the “gold standard” for IBD diagnosis,
disease activity and therapy outcome. For these reason new studies have
proposed an “IBD signature”, which consists in a panel of biomarkers used to
assess IBD. The above described approach characterizes “omics” and in this
review we will focus on proteomics.
Key words: Proteomics; Inflammatory bowel disease; Cronh’s disease; Ulcerative colitis;
Proteins; Biomarkers discovery
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Core tip: Patients' heterogeneity is a hallmark for inflammatory bowel diseases (IBD).
Some patients present limited bowel involvement and a mild course of the disease, others
develop very extensive, aggressive disease and variable response to therapy. In IBD,
there is a great need of patient stratification and of new biomarkers as part of a
personalized medicine approach to patient care. Biological therapies are more and more
widely used for IBD patients, because of their efficacy in patient’s refractory to other
drugs; still, biological treatments fail in 20%-40% of patients and, to date, no reliable
clinical or molecular predictor of response to biological therapeutic strategy has been
described. This review aims to collect the "omics" approach for research of serological
biomarkers of diagnosis, response to specific biological therapies in the IBD field.
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INFLAMMATORY BOWEL DISEASE
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main inflammatory
bowel  diseases  (IBD) [1 -4].  Despite  some  shared  characteristics,  they  can  be
distinguished by differences  in  genetic  predisposition,  risk  factors,  and clinical,
endoscopic  and  histological  features.  CD  is  characterized  by  diffuse  chronic
inflammation throughout the gastrointestinal tract, in a non-continuous manner[5]; UC
presents with inflammation limited to the colon, spreading continuously from the
rectum[6]. The pathogenesis of IBD is at present not completely unraveled; however,
genetically susceptible individuals seem to have a dysregulated mucosal immune
response to the commensal gut flora, which results in bowel inflammation[7]. IBD are
multi-factorial diseases[8] with reported alterations in the gut microbiota[9-12], activation
of different immune cell types[13-15],  changes in the vascular endothelium[16,17],  and
alterations in the tight junctions structure of colon epithelial cells[18-20].
Nowadays, the diagnostic and prognostic tools for IBD and the outcome of therapy
are largely based on evaluation of clinical symptoms in combination with endoscopy,
histology, radiology and non-specific biomarkers from serum or stools[21].
BIOMARKERS IN INFLAMMATORY BOWEL DISEASE
Inflammation in  IBD is  characterized by the  increased levels  of  some molecules
extensively validated but not all included in the laboratory routine. Some of them are
related  to  the  inflammatory  acute-phase  response,  coagulation  and  fibrinolysis
(fibrinogen,  plasminogen,  complement  components),  proteinase  inhibitors  (α1-
antitrypsin  and  α1-anti-chymotrypsin),  transport  proteins  (haptoglobin  and
ceruplasmin) and other serum proteins[22] and cytokines[23]. Elevated platelet and white
blood cell  counts may also indicate inflammation but they cannot be considered
strictly related to bowel inflammation[23]. C-reactive protein (CRP), anti-Saccaromyces
cerevisiae (ASCA) and anti-neutrophil cytoplasmic antibody are the most widely used
indicators. CRP has a short reaction time (6-10 h) and it is useful for the identification
of inflammatory disease activity especially in CD, but not in UC[24].  CRP has low
specificity enabling to differentiate between CD, UC and infectious colitis[21], and also
the 25% of IBD patients with demonstrable disease activity have CRP levels above the
normal threshold[22]. ASCA is an antibody used for the identification of CD patients
who are often positive (39%-79% of CD patients, 5%-15% UC patients)[25,26], however a
large part of healthy controls is also positive (14%-18%) to this antibody, limiting the
diagnostic  value  of  its  detection[27].  anti-neutrophil  cytoplasmic  antibodies  are
antibodies found in immune-mediated pathologies, such as rheumatoid arthritis and
Wegener’s granulomatosis[28], and have shown a different staining pattern in UC and
CD patients[29-31], but as for ASCA 32% of healthy population is also positive to them[32].
Another explored field in the search for IBD biomarkers is the analysis of stool
proteins, which can be dysregulated or abnormally present in patients. Stool markers
have the advantage of increased specificity for bowel inflammation and reflect any
mucosal  barrier  disruption.  Fecal  markers  can be  useful  to  diagnose  CD,  where
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inflammation is patchy and is possibly missed at endoscopy[33]. Fecal calprotectin (FC)
accounts  for  up  to  5%  of  the  neutrophil  granulocytes’  protein  content  with
chemotactic and antimicrobial activities. It is stable in stool for more than a week and
can resists  to bacterial  degradation[34].  FC is  not  a specific  marker for IBD, but it
correlates with increased disease activity at least in adults[35],  but not in pediatric
patients where was found with high sensitivity (98%), but only modest specificity
(68%)[36].  Disease location should also be taken into account when interpreting FC
levels.  Patients  with  ileal  CD may have  ulcers  even in  the  absence  of  markedly
elevated FC levels. Consequently, the cut-off values for ileal CD may differ from those
with ileocolic disease[37,38]. A study conducted by De Vos et al[39] has demonstrated that
Calprotectin decreased 2 wk after Infliximab administration predicts remission in
anti-TNF-naïve patients with UC. The increase of FC can also be a suitable marker for
the identification of relapse, given the fact that the levels are increased as early as 6
mo before clinical and endoscopic relapse[40]. Lactoferrin is an iron-binding protein
expressed by neutrophils  during inflammation and represents  a  defense against
infection as part of the innate immune system[41,42]. As a biomarker, Lactoferrin can
distinguish IBD from Irritable Bowel Syndrome, but not between CD and UC[27].
Although  many  non-invasive  biomarkers  have  been  described,  none  can  be
considered as the “gold standard” for IBD diagnosis, disease activity and therapy
outcome.  A  single  ideal  biomarker  is  very  unlikely  to  be  found.  As  for  other
pathologies as pancreatic cancer[43-46],  non-small  cell  lung cancer[47]  and colorectal
cancer[48]  new studies have proposed the idea of a “Biomarker Signature”, which
consists in a panel of biomarkers used to assess various pathological conditions and
response to therapy[49], and which is applicable also to IBD diagnosis and prognosis.
Table 1 summarizes the biomarkers commonly used for IBD.
PROTEOMIC APPROACH TO INFLAMMATORY BOWEL
DISEASE RESEARCH
Proteomics comprehensively studies the protein composition and abundance in a
given  cell  population  and  its  changes  under  biological  perturbations[50,51].  The
proteome may be considered the signature of a disease, in fact it is the result of the
interactions between the genetic background and environmental factors[49]. The novel
proteomic technologies now facilitate the analysis of transcriptome variations also in
the IBD context and have already provided with new candidate biomarkers[52]. They
help to investigate the inflammatory response, epithelial barrier function and gut
microbiome from different biological samples, i.e., serum/blood, colon samples and
feces. The proteomic strategies can be bottom-up and top-down (Figure 1). In the
bottom-up approach, purified proteins or complex protein mixtures are subjected to
proteolytic cleavage and the peptide products are analyzed by mass spectrometry
(MS). Conversely, the top-down approach is based either on the analysis of intact
proteins  followed by the  direct  measurement  of  fragment  ions  by MS or  on the
isolation of the protein by gel-based separative methods, protein gel elution and MS
analysis.
Proteomics in the study of IBD pathogenesis
By LC-MS analysis of colon mucosal biopsies from 10 patients with UC, Bennike et
al[53] identified 5711 quantifiable proteins classified by biological function, sub-cellular
location  and  molecular  function.  Forty-six  proteins  demonstrated  statistically
significant changes in mean abundance between UC biopsies and control biopsies;
among those proteins, the one with the largest mean fold abundance change was
lactotransferrin, which was 219 times more abundant in the UC group. The relative
abundance of lactotransferrin also correlated to the severity of tissue inflammation in
the patients with UC, as determined by the colon inflammation grade score based on
histology. Good correlation was found between the colon inflammation grade score
and the relative abundance of lactotransferrin in the tissue (0.82)[53]. Eleven of the 46
proteins identified in the UC biopsies are present in neutrophils and are associated
with  the  formation  of  neutrophil  extra-cellular  traps  which  are  released  from
neutrophils  in  response  to  inflammatory  stimuli[54,55],  and  are  a  sign  of  chronic
inflammation even in the absence of visible inflammation[54,56,57].
Proteomics has also investigated IBD-related immune-cell responses. Riaz et al[58]
compared Th1 and Th17 clones isolated from the intestinal mucosa of CD patients by
means  of  label-free  quantitative  mass-spectrometry  analysis,  which  led  to  the
identification of a total number of 7401 unique protein groups and demonstrated that
334 proteins were differentially expressed. The largest differences between the two
phenotypes were observed in such proteins with cytotoxic function as Granzyme B
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Table 1  Biomarkers in inflammatory bowel disease
Marker Setting Diagnostic accuracy Ref.
C-Reactive Protein (CRP) Serum Higher in CD vs UC Henriksen et al[24], 2008
25% IBD patients have levels above normal Vermeire et al[22], 2004
Anti-Saccharomyces cerevisiae Antibodies (ASCA) Serum 39%-79% CD positive Peyrin-Biroulet et al[25], 2015;
5%-15% UC positive Reumaux et al[26], 2004
14%-18% HC positive Bennike et al[27], 2014
Anti-neutrophil cytoplasmic antibodies (ANCA) Serum Different pattern in CD and UC Peeters et al[31], 2001;
Peyrin-Biroulet et al[30], 2007;
Reumaux et al[29], 2003
32% HC positive Bernstein et al[32], 2011
Calprotectin Colorectal mucus Higher in IBD vs HC Loktionov et al[79], 2016
Higher in UC vs CD
Calgranulin C (S100A12) Higher in UC vs CD
Eosinophil-derived neurotoxin (EDN) Higher in IBD vs HC
Higher in UC vs CD
Fecal calprotectin (FC) Stool It correlates with disease activity in adults Gisbert et al[35], 2009
Lactoferrin Stool It distinguishes IBD from IBS Bennike et al[27], 2014
CD: Crohn’s disease; UC: Ulcerative colitis; HC: Healthy controls; IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.
and perforin, which are lower in Th17 cells than in Th1 cells. Other differentially
expressed  proteins  with  higher  expression  in  the  Th1  clones  included  several
transcription factors with both known and unknown functions in CD4+ T-cells. The
most striking differences at quantitative analysis are about CD4+  T cells with Th1
phenotype having a much higher degree of  cytotoxic features as compared with
Th1/Th17 phenotype[58].
As discussed above, the disruption of the intestinal barrier is a typical event in IBD
pathogenesis. The intestinal epithelium is the largest surface exposed and coming into
contact with the external environment. The intestinal epithelial cells (IECs) are the
main component of the physical barrier between the luminal micro-environment and
the host and act as the host’s first line-of-defense against potential harmful stimulants.
They also represent the innate immunity within the gut mucosa[59].  Normally, the
intestinal epithelium is covered by a single layer of IECs, which are characterized by a
fast renewal rate, and act as a protective barrier against luminal antigens, but this
barrier  can be damaged,  thus promoting a  state  of  chronic  inflammation due to
mucosal immune cell  infiltration,  as is  typically observed in IBD patients[59].  The
molecular changes in the epithelial layer, extra-cellular matrix and junction proteins
in inflamed and non-inflamed intestinal tissue have been only partially addressed to
date. In 2012 Poulsen et al[60] analyzed the proteomic profiles of whole colonic biopsies
from  UC  patients  using  2D-gel  electrophoresis  and  MALDI-TOF  MS  for  the
identification  of  differently  expressed  protein  spots.  Forty-three  proteins  were
identified differentially expressed between UC inflamed and non-inflamed tissue,
including proteins involved in the energy metabolism and in oxidative stress[60].
Proteomic studies on isolated IECs obtained from surgical specimens of full-thickness
colonic  tissues  from UC-,  CD-affected  patients  and non-inflamed controls  were
analyzed by gel-based stable-isotope label  technologies (2D-DIGE and ICPL LC-
MS/MS) and immunoblot assay to evaluate any proteome changes. Moreover, the
results were verified on a group of patients not participating in the discovery phase[61].
The differential proteomic approaches have revealed changes in several molecules
involved in  extracellular  matrix,  mechano-transduction,  metabolic  rewiring and
autophagy that characterize quiescent UC and quiescent CD epithelial cells and they
may help understanding the complex mechanisms associated to IBD. UC patients are
characterized by cytoskeletal rearrangement and increased level of specific enzymes
that contribute to cell homeostasis, enabling cells to cope with energy requirements
and macro-autophagy. CD patients are characterized by metabolic rewiring to sustain
the cell metabolism, whereas autophagy and cell renewal are blunted[61-63]. Table 2
provides  a  summary  of  the  proteins  and  pathways  identified  by  the  proteomic
approach as involved in IBD pathogenesis.
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Figure 1
Figure 1  Schematic illustration of the difference between protein-based top-down and peptide-based bottom-up proteomics.
Proteomics for the identification of novel biomarkers
Another  approach  is  the  identification  of  biomarkers  useful  for  the  diagnosis,
treatment selection and response monitoring. A recent study focused on diagnosis has
identified a serological panel which demonstrates transmural intestinal injury and is
able  to  indicate  complications  in  CD  patients  with  70%  sensitivity  and  72.5%
specificity[64]. The increase of circulating epithelial component proteins may be a sign
of transmural intestinal injury and stricturing or fistulizing intestinal complications.
The serum biomarkers for the stratification of IBD patients are unable to distinguish
between CD and UC[65], while the proteomic profiles of colon biopsies can identify a
more precise signature of these diseases[61,66,67]. In 2016 Starr et al[68] established two
candidate biomarker panels:  A 5-protein panel  to discriminate IBD from control
patients and a 12-protein panel to distinguish CD from UC patients in children with a
new IBD diagnosis.
Proteomics has been applied to the identification of treatment-response biomarkers.
The anti-TNF drug called Infliximab is one of the most used drugs in IBD, but the
factors predicting the response and the molecular mechanisms that are related to the
loss of response or non-responsiveness are not completely known. Meuwis et al[69]
have analyzed sera from responder and non-responder CD patients at baseline and
then comparing sera throughout the induction period (week 4 for non-fistulizing and
week 10 for fistulizing patients) and have shown that the platelet aggregation Factor 4
(PF4) was higher in non-responders than responders to Infliximab therapy (both
before and after treatment). PF4 is considered as an acute-phase reactant because its
level increases with general inflammation, as already observed in the plasma of CD
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Table 2  Proteomics in inflammatory bowel disease pathogenesis
Protein Setting Diagnostic accuracy Ref.
Lactotransferrin UC vs HC biopsies It correlates to the colon
inflammation grade score
Bennike et al[53], 2015
Neutrophil extracellular traps
(NETs)
Sign of chronic inflammation
Granzyme B and Perforin CD Th1 and Th17 clones from
intestinal mucosa
Higher in Th1 vs Th17 Riaz et al[58], 2016
RORC and FOXP3
Glycerol-3-
phosphatedehydrogenase
UC biopsies inflamed vs non-
inflamed
Higher in inflamed vs non-inflamed
tissue
Poulsen et al[60], 2012
Alphaenolase Lower in inflamed vs non- inflamed
tissue
Keratins 10, 14, 19 UC intestinal epithelial cells Higher in QUC vs HC Moriggi et al[61], 2017
Keratin 8 Lower in QUC vs HC
Tricarboxylic acid cycle enzymes
Oxidative phosphorylation enzymes
Vinculin and α-tubulin
Keratin 8, 18 CD intestinal epithelial cells Lower in QCD vs HC
Heat shock cognate-70 (HSC70)
Vinculin and α-tubulin Higher in QCD vs HC
Fibrinopeptide A (FPA) CD serum Higher in CD vs HC Nanni et al[62], 2009
Complement 3 protein (C3)
Apolipoprotein A-IV
Apolipoprotein E Lower in CD vs HC
L-lactate dehydrogenase IBD and HC intestinal epithelial cells Higher in IBD vs HC; Higher in CD
vs UC
Shkoda et al[63], 2007
Carbonyl reductase
Keratin 19
Rho-GDI dissociation inhibitor α
Annexin 2 UC intestinal epithelial cells Higher in UC vs HC
Programmed cell death protein 8
(PDCD8)
IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; QCD: Quiescent Crohn’s disease; QUC: Quiescent ulcerative colitis; HC:
Healthy controls; CRC: Colorectal carcinoma.
patients[70-72]  .  Gazouli  et  al[73]  have compared sera before treatment and after IFX
induction (week 12) and successfully identified 15 proteins that were differentially
accumulated  in  the  sera,  most  of  them  modifying  the  activation  of  monocytes
/macrophages  and  directly  and  indirectly  regulating  the  differentiation  and
activation  of  CD4+  T-lymphocytes.  Also,  a  recent  study  by  Magnusson  et  al[74]
reported  on  the  proteomic  analysis  on  biopsies  obtained  from 6  UC patients  (3
responders and 3 non-responders) treated in vitro with or without Infliximab and also
from 43 UC patients’ sera at different time points: Baseline, week 2 and week 14.
Those  authors  have  shown  that  the  response  in  UC  patients  is  associated  with
reduced  monocyte  activation  2  wk  after  therapy  initiation,  suggesting  that  the
monocytes  of  these  patients  are  less  responsive  to  inflammatory  stimuli  when
reaching the intestinal mucosa. In therapy responders Infliximab has had influence on
Tenascin C, which might be a down-regulator of the two chemokines CCL2 (mcp-1)
and CXCL10 (IP-10)[74], which are produced by inflammatory cells and stromal cells,
recruit leucocytes, and are induced in inflamed UC mucosa[75-77]. Table 3 summarized
the potential biomarkers identified by proteomics in IBD.
CONCLUSION
In the IBD micro-environment a multitude of components interact. No information
about a single gene, a single molecule or microbe can exhaustively explain the events
that result from such a complex signaling. Also, the wide range of variability between
patients’ disease features and medical histories makes it difficult to understand how
every component of IBD acts and influences other components. On the other hand,
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Table 3  Proteomics in inflammatory bowel disease diagnosis and response to therapy
Proteins Setting Diagnostic accuracy Ref.
Platelet aggregation factor 4 (PF4) Responder vs non-responder’s CD
serum
Higher in non-responders Mewuis et al[69], 2008
Proteins that regulate CD4+ T-cell
activation
Serum before IFX treatment vs serum
after IFX induction period
Higher before treatment Gazouli et al[73], 2013
Proteins that regulate
monocytes/macrophages activation
Tenascin C Responder vs non-responder’s UC
serum
Higher in non-responders Magnusson et al[74], 2015
CD: Crohn’s disease; UC: Ulcerative colitis.
even if the diagnostic gold standard is endoscopy, the introduction of novel molecular
biomarkers in clinical practice has always nurtured hopes for new tools that can lead
to improvements in diagnostic accuracy. However, the low diagnostic performance of
the available markers strongly limits their use in clinical practice. Still, it is reasonable
to hypothesize that combining the modification of several biomarkers may identify a
sort of fingerprint for IBD with specific disease features.
Indeed, techniques and methodologies that can deal with a very large volume of
data and describe a wide picture, rather than focus on single alteration, are likely to
represent the necessary step forward in describing and comprehending IBD[78]. For all
these  reasons  omics  can  support  the  discovery  of  novel  molecular  interactions
through a better definition of relevant biological pathways and interactions, rather
than the analysis of the role of the perturbation of a single element. Omics can lead to
the identification of representative patterns of disease which may replace simple
biomarkers  in  clinical  practice  for  the  diagnosis,  monitoring  of  IBD and for  the
personalization  of  therapies  and  treatments.  Exploiting  omic  techniques  and
mastering big data analysis will  help researchers to embrace the complexity and
overcome the limitations of  deciphering inflammatory disorders away from any
restricted point of view. Table 3 provides a summary of the potential biomarkers
identified by proteomics in IBD.
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